East Mab — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

A Chinese antibody developer creating novel monoclonal antibody therapies for cancer and autoimmune diseases.

OncologyImmunology

Utilizes hybridoma and phage display platforms for the discovery and engineering of therapeutic monoclonal antibodies.

Leveraging China's efficient clinical trial ecosystem to rapidly generate human data for novel antibody candidates.

Pipeline attrition risk and intense competition may limit commercial potential for any single asset without strong differentiation.

Competes in the densely populated Chinese antibody development sector, where numerous companies are pursuing similar oncology and immunology targets.